Peptide data sheet
Survodutide
GLP-1 · BI 456906
Verdict
promisinginvestigational; no approved human use
By MrPepTalks Editorial
Reviewed for scientific accuracy · research information, not medical advice
Last updated Reviewed
Quick answer
Survodutide (BI 456906) is an investigational dual agonist that activates both the GLP-1 and glucagon receptors. It is commonly researched for weight management and for metabolic dysfunction-associated steatohepatitis (MASH). Mid-stage trials reported meaningful weight and liver-marker changes, which is why the verdict is Promising rather than Proven — it is still in clinical development, is not FDA-approved, and is not available for human use.
- Class
- GLP-1/glucagon dual receptor agonist (investigational)
- Half-life
- Supports once-weekly dosing in trials (exact human value not publicly established)
- FDA status
- Not FDA-approved; investigational, in clinical trials
Which form actually works?
Injectable (subcutaneous, once-weekly in trials)
Promising
The route used across the reported clinical trials. Weight and liver-marker results were reported here, but the compound remains investigational and is not approved for human use.
Third-Party Testing & Certificate of Analysis (COA)
A certificate of analysis (COA) is a lab document that reports what a specific batch of material actually contains. Reputable research suppliers publish one for every batch, tied to a lot number you can match against the vial you received.
- HPLC — purity
- High-performance liquid chromatography reports purity as a percentage: how much of the sample is the intended compound rather than impurities.
- Mass spectrometry (MS) — identity
- Mass spectrometry confirms identity by measuring the sample's molecular mass, so it matches the peptide the label names.
It also matters who ran the test. In-house results come from the seller's own lab; an independent third-party lab has no stake in the result, so its COA generally carries more weight. Look for a named testing laboratory, a batch or lot number, and a test date that lines up with the vial in hand.
New to reading one? This guide walks through a COA line by line: how to read a peptide COA.
Sources
- Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial (le Roux et al., Lancet Diabetes & Endocrinology, 2024).
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (Sanyal et al., N Engl J Med, 2024).
- Phase 2 dose-finding trial of survodutide (BI 456906) in adults with overweight or obesity (ClinicalTrials.gov: NCT04667377).
Related peptides
All GLP-1 →Frequently asked questions
No spam. Compliant with CAN-SPAM (US), CASL (Canada) & GDPR (EU) · one-click unsubscribe. See our Privacy Policy.